Related Experiment Video
Updated: Feb 8, 2026

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
Published on: October 24, 2016
A multidisciplinary diagnostic approach to pulmonary fibrosis in dogs and cats
Carol R Reinero1,2, Isabelle Masseau3, Kurt J Williams4
1BREATHE Clinic, Veterinary Health Center, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
Abstract:
Idiopathic pulmonary fibrosis (IPF) describes a severe, progressive, and ultimately fatal end-stage lung disorder in dogs and cats. The term IPF was coined in dogs and cats for 2 reasons: 1) the cause of the fibrosis at the time of diagnosis was unknown (i.e., presumed idiopathic); and 2) the condition was believed to resemble human IPF, the most common type of progressive fibrotic lung disease in people. However, pulmonary fibrosis in dogs and cats is not a single homogeneous disorder, does not consistently resemble all histologic features of human IPF, and is rarely exhaustively evaluated for an underlying cause. Fibrosis is a response to injury, and knowledge of the type of injury has critical implications for disease management, especially if identified before end-stage lesions occur. We offer an approach to a thorough diagnostic evaluation, including clinical, imaging, laboratory, and pathology data, which sets the stage for multidisciplinary discussions. Given that thoracic computed tomography (CT) is increasingly utilized to identify features compatible with pulmonary fibrosis in dogs and cats, we describe these CT patterns and their pitfalls. Diagnostic respiratory evaluations should investigate possible inciting causes, provide information about disease extent and severity, and identify comorbid disorders. Such evaluations will allow optimized therapy, including avoiding treatments that may have adverse effects or be overtly harmful. Importantly, although end-stage fibrotic lungs currently have no viable treatment, early recognition of known triggers of fibrosis could ultimately enable novel targeted therapy while there is still time to alter the clinical course.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

